Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06532682
PHASE4

Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes

Sponsor: The First Affiliated Hospital with Nanjing Medical University

View on ClinicalTrials.gov

Summary

Diabetic kidney disease (DKD) is a leading cause of chronic and end-stage kidney disease, affecting 25-40% of type 1 diabetes (T1D) patients and 5-40% of type 2 diabetes (T2D) patients. Despite standard treatments like ACE inhibitors and ARBs, many patients continue to develop DKD, indicating a need for better kidney protection. This study aims to evaluate the efficacy and safety of dapagliflozin combined with insulin in early DKD patients with T1DM, using ACEi/ARB as standard treatment, to provide new insights into kidney protection and support precision medicine goals.

Official title: Efficacy and Mechanism of Dapagliflozin Combined With Insulin in the Treatment of Early Diabetic Nephropathy in Patients With Type 1 Diabetes

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

54

Start Date

2024-07-01

Completion Date

2026-10-01

Last Updated

2024-08-01

Healthy Volunteers

No

Interventions

DRUG

dapagliflozin

dapagliflozin 5 MG/10 MG once daily

DRUG

ACE inhibitor

ACE inhibitor

Locations (1)

Nanjing Medical University First Affiliated Hospital

Nanjing, Jiangsu, China